SHMT Enzyme Acts as Tumor Suppressor by Preventing ROS-Driven DNA Damage
Drosophila study reveals SHMT loss accelerates cancer progression via oxidative genome instability, with vitamin B6 depletion amplifying the effect.
Summary
Researchers used a Drosophila cancer model to show that silencing the metabolic enzyme SHMT accelerates tumor growth by impairing thymidylate synthesis and triggering reactive oxygen species (ROS)-driven DNA damage. When SHMT was depleted alongside its cofactor PLP (the active form of vitamin B6), oxidative stress became so severe it paradoxically induced apoptosis in cancer cells, limiting tumor growth. Antioxidant treatment with N-acetyl cysteine reduced both DNA damage and tumor progression. These findings reveal a tumor suppressor role for SHMT and identify a novel gene-nutrient interaction between SHMT and PLP with potential therapeutic implications for certain cancer types.
Detailed Summary
One-carbon (1C) metabolism, centered on the enzyme serine hydroxymethyltransferase (SHMT), is critical for nucleotide synthesis, DNA methylation, and cellular redox balance. While SHMT overexpression has been linked to oncogenesis in multiple cancer types, a smaller body of evidence suggests SHMT can also act as a tumor suppressor — particularly SHMT1 in hepatocellular and renal cell carcinoma. The molecular mechanisms behind this suppressor role remained poorly understood, motivating this study.
Using a well-established Drosophila eye disc cancer model — where oncogenic RasV12 is expressed alongside RNAi silencing of the polarity gene Disc large (Dlg) — the authors investigated what happens when SHMT is additionally depleted. GFP labeling allowed quantification of primary tumor size and invasive spread into larval brains. RT-qPCR confirmed effective SHMT knockdown. The team also manipulated the folate pathway downstream of SHMT by silencing thymidylate synthase (TS) or supplementing with exogenous thymidylate (dTMP), and tested antioxidant intervention with N-acetyl cysteine (NAC).
SHMT silencing in RasV12DlgRNAi cells significantly enlarged tumors and increased invasiveness into the ventral nerve cord. This effect was mediated through impaired thymidylate biosynthesis in the folate pathway: silencing TS phenocopied SHMT loss, while dTMP supplementation partially rescued tumor overgrowth. SHMT depletion also caused measurable DNA double-strand breaks (marked by γH2AX) and chromosomal aberrations, and sensitized cancer cells to additional genotoxic stressors including X-rays and hydroxyurea. Mechanistic analysis revealed that ROS generation was the primary driver of this genomic instability, with replicative stress and impaired DNA repair as secondary contributors. Strikingly, NAC treatment significantly attenuated both DNA damage and tumor progression, confirming the ROS-genome instability axis.
The most novel finding involves the interaction between SHMT and its enzymatic cofactor PLP (pyridoxal 5'-phosphate, the active form of vitamin B6). When both SHMT and PLP were simultaneously depleted, oxidative stress reached a threshold that triggered extensive apoptosis specifically in RasV12DlgRNAi cancer cells — paradoxically limiting tumor growth rather than promoting it. This synergistic gene-nutrient interaction represents a previously unrecognized regulatory axis with potential therapeutic relevance.
These results support a context-dependent tumor suppressor function for SHMT: at moderate depletion levels, loss of SHMT destabilizes the genome and fuels cancer progression via ROS; at extreme depletion (compounded by PLP deficiency), the resulting damage crosses a threshold that kills cancer cells. The study also highlights how dietary micronutrient status (vitamin B6/PLP) could modulate cancer risk and progression through its interaction with one-carbon metabolism enzymes.
Key Findings
- SHMT silencing in RasV12DlgRNAi Drosophila tumors significantly increases tumor size and brain invasion.
- Tumor progression is driven primarily by ROS-induced DNA and chromosomal damage, not replicative stress alone.
- Antioxidant NAC treatment substantially reduces both DNA damage and tumor growth after SHMT loss.
- Combined SHMT and PLP depletion induces apoptosis in cancer cells, paradoxically limiting tumor growth.
- dTMP supplementation rescues tumor overgrowth, confirming the folate-thymidylate pathway as the key mechanism.
Methodology
The study used a Drosophila eye disc model co-expressing oncogenic RasV12 and Dlg RNAi to generate malignant tumors, with additional RNAi-mediated SHMT knockdown. Tumor progression was quantified via GFP area measurements and brain invasion scoring; DNA damage was assessed with γH2AX staining and chromosomal analysis. Mechanistic interventions included dTMP supplementation, NAC antioxidant treatment, X-ray/hydroxyurea genotoxic stress, and combinatorial PLP dietary manipulation.
Study Limitations
The study is conducted entirely in Drosophila, and translation to human cancers requires validation in mammalian models and patient data. Many human epidemiological associations between SHMT1 variants and cancer risk are based on small sample sizes. The precise threshold between tumor-promoting and tumor-suppressing levels of SHMT/PLP depletion remains undefined.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.